Literature DB >> 23074321

Persistence and antiviral resistance of varicella zoster virus in hematological patients.

Martha T van der Beek1, Clementien L Vermont, Robbert G M Bredius, Erik W A Marijt, Caroline S van der Blij-de Brouwer, Aloys C M Kroes, Eric C J Claas, Ann C T M Vossen.   

Abstract

BACKGROUND: Varicella zoster virus (VZV) infections are a relevant cause of morbidity and mortality in hematological patients and especially in hematopoietic stem cell transplant (HSCT) recipients. The present study aimed to investigate the prevalence and clinical significance of viral persistence and antiviral resistance by systematically analyzing all episodes of VZV diagnosed in our laboratory in pediatric and adult hematological patients between 2007 and 2010.
METHODS: Patient charts were reviewed to document patient and disease characteristics. VZV loads were determined in all available clinical samples from the day of diagnosis and thereafter. Persistent VZV infection was defined as a VZV infection that lasted at least 7 days. Analysis of resistance was performed in all patients with persistent VZV infection by sequence analysis of viral thymidine kinase and DNA polymerase genes.
RESULTS: In total, 89 episodes occurred in 87 patients, of whom 65 were recipients of an allogeneic HSCT. Follow-up samples were available in 54 episodes. Persistent VZV was demonstrated in 32 of these episodes (59%). Complications occurred in 16 of the persistent episodes (50%) vs 2 of 22 nonpersistent episodes (9%). Mutations possibly associated with resistance were found in 27% of patients with persistent VZV, including patients with treatment-unresponsive dermatomal zoster that progressed to severe retinal or cerebral infection.
CONCLUSIONS: In hematological patients, VZV-related complications occur frequently, especially in persistent infections. Antiviral resistance is a relevant factor in persistent infections and needs to be investigated in various affected body sites, especially when clinical suspicion of treatment failure arises.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23074321     DOI: 10.1093/cid/cis879

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

1.  Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation.

Authors:  Preeti Bhalla; Graeme N Forrest; Michael Gershon; Yan Zhou; Jason Chen; Philip LaRussa; Sharon Steinberg; Anne A Gershon
Journal:  Clin Infect Dis       Date:  2014-12-01       Impact factor: 9.079

2.  Drug resistance of clinical varicella-zoster virus strains confirmed by recombinant thymidine kinase expression and by targeted resistance mutagenesis of a cloned wild-type isolate.

Authors:  Anne-Kathrin Brunnemann; Kathrin Bohn-Wippert; Roland Zell; Andreas Henke; Martin Walther; Oliver Braum; Gregor Maschkowitz; Helmut Fickenscher; Andreas Sauerbrei; Andi Krumbholz
Journal:  Antimicrob Agents Chemother       Date:  2015-02-23       Impact factor: 5.191

3.  Antiviral Drugs Against Herpesviruses.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Advances and Perspectives in the Management of Varicella-Zoster Virus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Molecules       Date:  2021-02-20       Impact factor: 4.411

5.  Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus.

Authors:  Larissa Henze; Christoph Buhl; Michael Sandherr; Oliver A Cornely; Werner J Heinz; Yascha Khodamoradi; Til Ramon Kiderlen; Philipp Koehler; Alrun Seidler; Rosanne Sprute; Martin Schmidt-Hieber; Marie von Lilienfeld-Toal
Journal:  Ann Hematol       Date:  2022-01-07       Impact factor: 3.673

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.